TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DORYX MPC

DOXYCYCLINE HYCLATE
Approved 2005-05-06
Jump to: Indications Approvals Trials Competitors Safety Patents
5
Indications
--
Phase 3 Trials
1
Priority Reviews
20
Years on Market

Details

Status
Discontinued
First Approved
2005-05-06
Routes
ORAL
Dosage Forms
TABLET, DELAYED RELEASE

Companies

MAYNE PHARMA
Active Ingredient: DOXYCYCLINE HYCLATE

DORYX MPC Approval History

Loading approval history...

What DORYX MPC Treats

5 FDA approvals

Originally approved for its first indication in 2005 . Covers 5 distinct patient populations.

  • Other (5)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DORYX MPC FDA Label Details

Pro

DORYX MPC Patents & Exclusivity

Latest Patent: Dec 2034

Patents (28 active)

US9446057 Expires Dec 23, 2034
US9295652 Expires Oct 23, 2034
US9511031 Expires Oct 23, 2034
US8715724 Expires Feb 3, 2028
+ 18 more patents
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA050795 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.